News
Academy
Publications
Media
Conferences
Columns
Resources
Webcasts
Subscribe

|Articles|September 11, 2012

PRO Experts Discuss New Revisions to Guidance

Author(s)Reid Paul

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Clinical trials are subject to multiple real-world variables, including varying site competence, patient data variability, changes in the standard of care and fundamental uncertainties about the drug's effect size. Credit: Stock.Adobe.com/photon_photo

De-Risking Development: Prioritizing Robustness in Trial Design

February 2nd 2026

Clinical Operations Teams Adjust to Evidence and Engagement Gaps

ByCharlie Paterson,Andy Studna, Senior Editor

February 2nd 2026

© adimas - © adimas - stock.adobe.com

New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN

ByAndy Studna, Senior Editor

January 30th 2026

Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches

ByCharlie Paterson,Andy Studna, Senior Editor

January 30th 2026

ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI

ByAndy Studna, Senior Editor

January 30th 2026

Trending on Applied Clinical Trials Online

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN

Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations

Clinical Operations Teams Adjust to Evidence and Engagement Gaps

Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches